BAY 1211163
Alternative Names: BAY-1211163Latest Information Update: 28 Dec 2023
At a glance
- Originator Bayer
- Class
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Adult respiratory distress syndrome
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Adult-respiratory-distress-syndrome in Germany (Inhalation)
- 21 Sep 2023 Bayer terminates a phase I trial in Adult respiratory distress syndrome in Germany (Inhalation) due to the company decision (NCT04609943)
- 24 Nov 2020 Phase-I clinical trials in Adult respiratory distress syndrome in Germany (Inhalation) (NCT04609943)